Kisspeptin-10

Kisspeptin-10: A Scientific Review

Based on peer-reviewed literature — see References. Last updated: April 2026.

The Short Version

Kisspeptin is one of the most biologically important peptides discovered in the past thirty years. It is the master upstream regulator of human reproductive function — the “switch” that the brain uses to activate puberty and maintain adult fertility. Without functional kisspeptin signalling, humans fail to develop sexually and remain infertile regardless of otherwise intact gonads and pituitary glands. With activating mutations, puberty begins years too early.

Three threads of evidence distinguish kisspeptin from most peptides in this series. The genetic proof is airtight: loss-of-function mutations in KISS1 or KISS1R in humans produce a completely predictable and specific phenotype — absent puberty and infertility — while gain-of-function mutations produce precocious puberty.^[1][2] The human clinical evidence is real and controlled: multiple randomised trials at Imperial College London have demonstrated that kisspeptin-54 can trigger oocyte maturation in IVF cycles with live birth rates of 45–62% per transfer and no cases of severe OHSS in high-risk patients.^[7] The community use is pharmacologically confused: most commercial use is of KP-10, not KP-54, but KP-10’s 4-minute half-life severely limits its therapeutic utility, and all the clinical IVF and FHA evidence comes from KP-54.

Discovery: Three Labs, One Molecule

The KISS1 gene was first identified in the late 1990s as a metastasis suppressor gene in melanoma cells. The gene product was named “metastin” by Ohtaki and colleagues at Takeda (2001), who characterised the KISS1-encoded peptide as a ligand for the orphan receptor GPR54.^[3] The reproductive role was unknown until 2003, when two simultaneously published papers changed the field entirely:

De Roux et al. and Seminara et al. independently identified loss-of-function mutations in the GPR54 receptor gene (KISS1R) in patients from consanguineous families with hypogonadotropic hypogonadism — absent puberty, low LH/FSH, prepubertal sex hormone levels, and infertility, despite structurally intact pituitaries and gonads.^[1][2] GPR54 knockout mice phenocopied the human syndrome. Despite the identification of KISS1 products in 2001, the reproductive aspect remained undiscovered until these simultaneous 2003 publications revealed the correlation of the kisspeptin system with the HPG axis and its crucial function in puberty onset and fertility. Activating mutations in KISS1R subsequently confirmed the reverse: central precocious puberty — completing the proof that kisspeptin signalling is both necessary and sufficient for driving reproductive axis activation.

The Kisspeptin Family: Peptides and Their Sizes

The KISS1 gene encodes a 145-amino acid prepropeptide processed into four bioactive C-terminal fragments, all sharing the same C-terminal decapeptide (KP-10) as their core active sequence:

All four forms bind KISS1R with equivalent affinity and produce the same intracellular signalling cascade. KP-54’s 7-fold longer half-life compared to KP-10 makes it substantially more suitable for sustained clinical applications. The clinical utility of all kisspeptins is limited by their short duration of action and the need for parenteral administration.^[10]

Mechanism: The Master Regulator of GnRH Pulsatility

The central circuit

Kisspeptin’s mechanism places it upstream of every other component of the reproductive hormonal axis, including GnRH. Kisspeptin neurons in the hypothalamic arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) secrete kisspeptin → KISS1R activation on GnRH neurons → Gq/11 coupling → phospholipase C → IP&sub3; + DAG → intracellular Ca²+ rise → GnRH neuron depolarisation → GnRH pulse secretion → pituitary gonadotrophs → LH + FSH secretion → gonadal function. In vitro experiments confirm that kisspeptin-10 fails to stimulate LH or FSH release from isolated pituitary tissue — all observed gonadotropin responses depend on an intact hypothalamus. This means kisspeptin’s effect is strictly hypothalamus-dependent and allows differentiation of hypothalamic from pituitary causes of hypogonadism.^[4]

The KNDy neuron: the pulse generator

The ARC kisspeptin neurons co-express neurokinin B (NKB) and dynorphin — collectively termed KNDy neurons. Neurokinin B activates NK3R on other KNDy neurons → positive autocrine/paracrine feedback → synchronised kisspeptin burst release → GnRH pulse. Dynorphin inhibits NK3R signalling → terminates the KNDy burst → allows pulse reset. This NKB-kisspeptin-dynorphin autoregulatory circuit in the ARC is currently understood as the primary GnRH pulse generator.^[10]

Sexual dimorphism and menstrual cycle phase effects

⚠️ A pharmacologically critical finding: in healthy women during the follicular phase of the menstrual cycle, no alterations in serum gonadotropins were observed after IV bolus, subcutaneous bolus, or IV infusion of kisspeptin-10 at maximal doses. In women during the preovulatory phase, serum LH and FSH were elevated after IV bolus kisspeptin-10 (10 nmol/kg).^[5] Kisspeptin-10 does not work at all in women during the follicular phase — the phase that comprises the majority of the menstrual cycle. Any community use of KP-10 by women without accounting for menstrual cycle phase is pharmacologically likely to produce no response during the majority of the cycle.

Human Clinical Evidence

LH pulse frequency in men (George et al. 2011)

IV bolus KP-10 doses 0.01–3.0 µg/kg in healthy men produced a rapid and dose-dependent rise in serum LH concentration, with maximal stimulation at 1 µg/kg (from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes). Administration of 3 µg/kg elicited a reduced response vs. 1 µg/kg — an inverted dose-response suggesting receptor desensitisation at supratherapeutic doses. Infusion of KP-10 at 4 µg/kg/h for 22.5 hours increased LH from 5.4 to 20.8 IU/L and serum testosterone from 16.6 to 24.0 nmol/L.^[4]

IVF oocyte maturation trigger: the best clinical evidence

The most rigorously controlled clinical data for any kisspeptin involves kisspeptin-54 as an oocyte maturation trigger in IVF. Following a standard recombinant FSH/GnRH antagonist protocol, oocyte maturation occurred in 95% of women. At all doses of kisspeptin-54, biochemical pregnancy, clinical pregnancy, and live birth rates per transfer were 63%, 53%, and 45%, respectively. Highest pregnancy rates were observed following 9.6 nmol/kg kisspeptin-54 (85%, 77%, and 62%). No woman developed moderate, severe, or critical OHSS.^[7]

Hypothalamic amenorrhea (FHA)

Twice-weekly subcutaneous KP-54 for 8 weeks produced an increase in gonadotropins from the first dose, with a comparable increase by day 14, and the response remained consistent after 8 weeks. Kisspeptin-54 administration twice weekly resulted in a lower degree of desensitisation compared to twice-daily administration. However, the protocol did not restore menstruation in women with hypothalamic amenorrhoea.^[8] This is important: FHA reflects a complex metabolic and stress-driven suppression of kisspeptin neurons, not simply kisspeptin deficiency. Exogenous kisspeptin partially overcomes this suppression, but the underlying energy deficit driving KNDy neuron silencing is not reversed by kisspeptin administration alone.

Clinical evidence summary

Kisspeptin-10 vs. Kisspeptin-54: The Clinical Relevance Gap

MVT-602: The Next-Generation Analogue

MVT-602, a KISS1R agonist analogue developed by Myovant Sciences, has been studied in Phase 1/2 trials. MVT-602 induced an LH surge of similar amplitude to that of native KP-54, however the duration of the LH rise was markedly prolonged (time of peak LH: MVT-602 21–22 hours vs. KP-54 4.7 hours), resulting in a more than four-fold increase in the area under the LH exposure curve.^[11] MVT-602’s prolonged LH elevation more closely resembles the physiological mid-cycle LH surge, potentially offering superior IVF trigger performance. This represents the next wave of kisspeptin pharmacology — analogue engineering for improved clinical performance.

Regulatory Status

Desensitisation: The Continuous vs. Pulsatile Problem

In a pattern analogous to continuous GnRH administration, continuous kisspeptin administration leads to KISS1R downregulation. The George et al. study noted that LH pulses were obscured at high continuous infusion rates. The FHA study found reduced desensitisation with twice-weekly vs. twice-daily KP-54 administration. Pulsatile or intermittent kisspeptin delivery maintains HPG axis responsiveness; continuous high-dose delivery risks receptor downregulation or, at extreme doses, suppression of the reproductive axis — the same fundamental pharmacological constraint that applies to GnRH agonist therapy.^[4]

Common Misconceptions

“Kisspeptin-10 is what the clinical trials used.”

⚠️ Most completed controlled clinical trials used kisspeptin-54. KP-10 has been studied in pharmacodynamic human studies but not in therapeutic trials for IVF triggering, FHA restoration, or IHH treatment. The evidence base for clinical efficacy belongs almost entirely to KP-54.

“Kisspeptin is natural and upstream, so it’s safer than other hormones.”

Upstream positioning in the HPG axis does not confer safety. Kisspeptin can desensitise its receptor with continuous exposure, could drive supraphysiological LH surges in responsive individuals, and the effects of chronic exogenous KP-10 administration on the GnRH pulse generator in healthy adults are not characterised.

“KP-10 and KP-54 are basically the same, just different sizes.”

They share the same receptor and identical intracellular signalling, but a 7-fold difference in half-life translates to a completely different exposure-response relationship in vivo. This is particularly important for sustained kisspeptin receptor engagement needed for pulsatile GnRH release.

Frequently Asked Questions

Is kisspeptin a treatment for low testosterone?

Kisspeptin stimulates endogenous testosterone by activating the HPG axis upstream. It will only work if the deficiency is hypothalamic (GnRH neuron dysfunction, as in CHH/Kallmann or FHA) and the pituitary and gonads are functional. It does not work in primary hypogonadism (testicular failure) or pituitary gonadotroph failure.^[10]

Can kisspeptin help with functional hypothalamic amenorrhea?

Clinical studies show KP-54 can partially restore LH pulsatility in FHA, but menstrual restoration in the studied protocols was not demonstrated.^[8] The primary treatment for FHA remains addressing the underlying energy deficit. Kisspeptin may have a future adjunctive role, but this remains unvalidated.

How does kisspeptin compare to gonadorelin for HPG axis stimulation?

Gonadorelin acts directly at the pituitary GnRH receptor; kisspeptin acts upstream at hypothalamic GnRH neurons. Both ultimately produce pulsatile GnRH release. Gonadorelin requires a pump for true pulsatile delivery in most clinical contexts. The IVF evidence base strongly favours kisspeptin-54 as an ovulation trigger; gonadorelin’s evidence base is stronger for CHH spermatogenesis induction. Neither is approved in the US.

Key Takeaways

1. Kisspeptin is the master upstream regulator of the HPG axis — the only known peptide whose loss of function specifically abolishes puberty and reproductive function while leaving all other pituitary axes intact. Its obligate role is confirmed by genetic evidence.^[1][2]
2. Kisspeptin-10 is the minimal bioactive fragment with full KISS1R affinity and the complete signalling cascade. Its 4-minute half-life severely limits clinical utility compared to KP-54 (28 minutes), and most therapeutic clinical trials used KP-54.
3. The clinical evidence for kisspeptin is genuinely good — in the right indications with the right form. The Imperial College IVF trigger data (95% oocyte maturation, 45–62% live birth rates, zero severe OHSS) represents some of the most clinically meaningful peptide data in this series. This evidence belongs to KP-54 in properly conducted IVF cycles.^[7]
4. ⚠️ The sexual dimorphism finding is a critical clinical caveat. KP-10 produces no gonadotropin response in women during the follicular phase — the phase comprising the majority of the menstrual cycle. Community use without phase-specific timing will have no pharmacological effect during this period.^[5]
5. ⚠️ The community market sells KP-10; the clinical literature studied KP-54. This mismatch between what is commercially available and what has been clinically validated is the central evidentiary problem for anyone attempting to translate the kisspeptin evidence base into community use.
6. MVT-602 represents the next generation — a KISS1R agonist analogue with a prolonged LH surge profile that more closely resembles the natural mid-cycle surge and may eventually find a path to regulatory approval.^[11]

References